ALVR Insider Trading
Insider Ownership Percentage: 32.07%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $82,278.96
AlloVir Share Price & Price History
Current Price: $9.71
Price Change: ▼ Price Decrease of -0.34 (-3.38%)
As of 02/10/2025 05:00 PM ET
AlloVir Insider Trading History
AlloVir Institutional Trading History
Data available starting January 2016
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Read More on AlloVir
Volume
20,504 shs
Average Volume
37,427 shs
Market Capitalization
$48.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.65
Who are the company insiders with the largest holdings of AlloVir?
Who are the major institutional investors of AlloVir?
Which major investors are selling AlloVir stock?
Within the last quarter, ALVR stock was sold by these institutional investors:
- BML Capital Management LLC
During the previous year, company insiders that have sold AlloVir company stock include:
- Gilead Sciences, Inc (Major Shareholder)
- Vikas Sinha (Insider)
- Diana Brainard (CEO)
- Edward Miller (General Counsel)
Learn More investors selling AlloVir stock.
Which major investors are buying AlloVir stock?
Within the previous quarter, ALVR stock was bought by institutional investors including:
- Raymond James Financial Inc.